表紙
市場調査レポート

心筋梗塞治療薬の世界市場:2016年〜2020年

Global Myocardial Infarction Drugs Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 354392
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
心筋梗塞治療薬の世界市場:2016年〜2020年 Global Myocardial Infarction Drugs Market 2016-2020
出版日: 2016年03月08日 ページ情報: 英文 75 Pages
概要

世界の心筋梗塞治療薬の市場は2016年から2020年にかけて0.41%のCAGR (複合年間成長率) で拡大することが予測されています。

当レポートでは、世界の心筋梗塞治療薬の市場を調査し、市場および製品の概要、主要ベンダーの提供製品、疾患の概要、パイプラインの動向、市場全体および薬剤クラス・心電図パターン・薬剤タイプ・地域別の市場規模の推移と予測、市場への影響因子の分析、主な動向、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • 市場概要
  • 主要ベンダーの製品

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

  • 主な市場ハイライト
  • 主な購買基準

第5章 疾患の概要

  • 心筋梗塞の各種タイプ
  • 病態生理
  • リスク因子
  • 診断
  • 管理

第6章 疫学・経済的負担

第7章 パイプライン分析

  • Canakinumab
  • MyoCell
  • MultiStem therapy
  • CLBS10
  • Prochymal
  • Revascor
  • CicloMulsion
  • PP-099
  • NP202
  • CAP-1002
  • Revacept
  • CSL112

第8章 市場環境

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第9章 市場分析:薬剤クラス別

  • ベータ遮断薬
  • ACE阻害剤
  • ARB
  • 血管拡張薬
  • 抗血栓薬
  • 血栓溶解薬
  • 糖蛋白IIb/IIIa阻害剤
  • 抗異常脂質血症薬
  • カルシウム拮抗薬
  • 鎮痛薬

第10章 市場分析:心電図パターン別

  • NSTEMI (非ST上昇型心筋梗塞)
  • STEMI (ST上昇型心筋梗塞)

第11章 市場分析:タイプ別

  • ブランド薬
  • ジェネリック薬

第12章 市場分析:地域別

  • 世界市場の推移と予測:地域別
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋

第13章 市場成長因子

  • 高齢者人口の増加
  • 坐位の多いライフスタイル
  • 肥満の拡大
  • 慢性疾患の高い発症率

第14章 市場成長因子の影響

第15章 市場課題

  • 診断の遅れ
  • 代替療法
  • ジェネリック薬の広範な利用

第16章 成長因子と課題の影響

第17章 市場動向

  • 疾患の認知度の上昇
  • 戦略的提携
  • R&Dの活発化
  • ステントグラフト利用の拡大

第18章 ベンダー情勢

  • 競合シナリオ
  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi
  • その他の有力ベンダー

第19章 付録

第20章 Technavioについて

図表

目次
Product Code: IRTNTR8952

About Myocardial Infarction Drugs

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

Technavio's analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • advanceCOR
  • Armaron Bio
  • Athersys
  • BioVascular
  • BMS
  • Caladrius
  • Capricor
  • CSL Behring
  • GNT Pharma
  • GSK
  • Ischemix
  • Mesoblast
  • NeuroVive
  • Osiris Therapeutics
  • PledPharma
  • RegeneRx
  • Teva Pharmaceuticals
  • TiGenix
  • US Stem Cell
  • Ventrix

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Alternative therapies
  • For a full, detailed list, view our report

Market trend

  • Growing awareness of disease
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Disease overview

  • Types of myocardial infarction
  • Pathophysiology
  • Risk factors
  • Diagnosis
  • Management

PART 06: Epidemiology and economic burden

  • Burden of disease

PART 07: Pipeline analysis

  • Canakinumab
  • MyoCell
  • MultiStem therapy
  • CLBS10
  • Prochymal
  • Revascor
  • CicloMulsion
  • PP-099
  • NP202
  • CAP-1002
  • Revacept
  • CSL112

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by drug class

  • Beta blockers
  • ACE inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic agents
  • Thrombolytics
  • Glycoprotein IIb/IIIa inhibitors
  • Anti-dyslipidemic drugs
  • Calcium channel blockers
  • Analgesics

PART 10: Market segmentation by EKG appearance

  • NSTEMI
  • STEMI

PART 11: Market segmentation by type

  • Brand-name drugs
  • Generic drugs

PART 12: Geographical segmentation

  • Global myocardial infarction drugs market segmentation by geography 2015-2020
  • Myocardial infarction drugs market in Americas
  • Myocardial infarction drugs market in EMEA
  • Myocardial infarction drugs market in APAC

PART 13: Market drivers

  • Increase in older population
  • Sedentary lifestyle
  • Rise in obesity
  • High prevalence of chronic conditions

PART 14: Impact of drivers

PART 15: Market challenges

  • Delayed diagnosis
  • Alternative therapies
  • Extensive use of generics

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Growing awareness of disease
  • Strategic alliances
  • Increased R&D
  • Prevalent use of stent grafts

PART 18: Vendor landscape

  • Competitive scenario
  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for myocardial infarction drugs
  • Exhibit 03: Pathophysiology of myocardial infarction
  • Exhibit 04: Risk factors of myocardial infarction
  • Exhibit 05: Diagnostic techniques for myocardial infarction
  • Exhibit 06: Treatment options for myocardial infarction
  • Exhibit 07: Projected prevalence of CVDs in US
  • Exhibit 08: Projected economic burden for CVDs in US
  • Exhibit 09: Pipeline portfolio: Myocardial infarction
  • Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions)
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015
  • Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015
  • Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015
  • Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Impact of drivers and challenges
  • Exhibit 22: AstraZeneca: Business segmentation by revenue 2014
  • Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
  • Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
  • Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
  • Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
  • Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
  • Exhibit 28: AstraZeneca: Key takeaways
  • Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
  • Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
  • Exhibit 31: Bayer HealthCare: Key takeaways
  • Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
  • Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
  • Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
  • Exhibit 35: Eli Lilly: Key takeaways
  • Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
  • Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
  • Exhibit 38: Novartis: Key takeaways
  • Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
  • Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
  • Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
  • Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
  • Exhibit 43: Pfizer: Key takeaways
  • Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
  • Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
  • Exhibit 46: Sanofi: Key takeaways
Back to Top